Latest Articles
- Pneumonia and alcohol use disorder: Implications for treatment
Patients with alcohol use disorder are at increased risk for Streptococcus pneumoniae but not resistant gram-negative infections.
- Irritable bowel syndrome with diarrhea: Treatment is a work in progress
Understanding of its mechanisms is progressing, and treatments are increasingly targeted to the individual etiology.
- Does a short QT interval increase the risk of cardiac death in healthy people?
No, but it may warrant further investigation to determine if the patient is at risk.
- Cytokines and the still-baffling clinical biology of COVID-19
The primary culprit is not certain. Is it all immune damage, or is the continued persistence of coronavirus playing a role?
- Cytokine storm and the prospects for immunotherapy with COVID-19
Despite gaping holes in our knowledge, treatment is evolving.
- Glucocorticoid-induced osteoporosis: Insights for the clinician
Glucocorticoids cause significant bone loss, predominantly affecting trabecular bone, with consequent fragility fractures.
- Perioperative infection: Are we sure what to focus on?
Which immunosuppressive drugs pose the greater danger in the perioperative period: the newer biologics or corticosteroids?
- Is it safe to continue biologic agents during surgery in patients with inflammatory bowel disease?
Patients taking monoclonal antibodies can continue taking them, but small-molecule drugs should be withheld.
- Denosumab cessation
Bone loss is rapid if patients miss injections. Clinicians can take extra measures to ensure patients get appropriate treatment.